239-OR: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Four-Period, Crossover Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Three Dose Levels of PB201 as Monotherapy in Subjects with Type 2 Diabetes Mellitus
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes"
DOI: 10.2337/db21-239-or
Abstract: Background: PB201, a dual-acting glucokinase activator (GKA), increases glucose stimulated insulin secretion, promotes glycogen synthesis and reduces hepatic glucose output by targeting both pancreatic and hepatic glucokinase. As a partial GKA, PB201 maintains efficacy while… read more here.
Keywords: dose levels; levels pb201; period; period crossover ... See more keywords